Last reviewed · How we verify
TOOKAD® Soluble
TOOKAD Soluble is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature.
TOOKAD Soluble is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature. Used for Localized prostate cancer (intermediate and high-risk disease).
At a glance
| Generic name | TOOKAD® Soluble |
|---|---|
| Also known as | WST11 |
| Sponsor | Steba Biotech S.A. |
| Drug class | Photodynamic therapy agent |
| Target | Vascular endothelial cells (non-receptor mediated phototoxicity) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TOOKAD (palladium bacteriopheophorbide) is a photosensitizer that, when activated by near-infrared light, produces singlet oxygen and reactive oxygen species that selectively damage tumor blood vessels, leading to tumor necrosis. The drug is administered intravenously and then activated by transurethral light delivery, making it particularly suited for localized tumors accessible to light delivery.
Approved indications
- Localized prostate cancer (intermediate and high-risk disease)
Common side effects
- Urinary symptoms (dysuria, frequency, urgency)
- Perineal pain
- Urinary retention
- Hematuria
- Phototoxicity reactions
Key clinical trials
- Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. (PHASE2)
- Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer (PHASE1, PHASE2)
- European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up
- Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. (PHASE3)
- Study of WST11 in Patients With Localized Prostate Cancer (PHASE2)
- Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer (PHASE3)
- Study Using WST11 in Patients With Localized Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TOOKAD® Soluble CI brief — competitive landscape report
- TOOKAD® Soluble updates RSS · CI watch RSS
- Steba Biotech S.A. portfolio CI